When the DREAM is gone:from basic science to future prospectives in pain management and beyond

Bibliography

• BERRIDGE MJ, LIPP P, BOOTMAN MD: The versatility and universality of calcium signalling. Nat. Rev Ma Cell. Biol. (2000) 1:11–21.
   PubMed Web of Science ®Google Scholar
• BURGOYNE RD, WEISS JL: The neuronal calcium sensor family of Ca2±-binding proteins. Biochent. J. (2001) 353:1–12.
   PubMed Web of Science ®Google Scholar
• BUXBAUM JD, CHOI E-K, LUO Y etal.: Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat. Med. (1998) 4:1177–1181.
   Google Scholar
• •First published report of CS/DREAM as a PS-binding partner. Overexpression of CS enhances the levels of the caspase-3-derived cleavage fragment of PS. Given the association between AD, neurodegeneration (apoptosis) and increased Ca2+ levels, the PS-CS association was suggested to contribute to perturbed Ca 2+ homeostasis and apoptosis in AD.
   Google Scholar
• CARRION AM, LINK WA, LEDO F, MELLSTROM B, NARANJO JR: DREAM is a Ca2+-regulated transcriptional repressor. Nature (1999) 398:80–84.
   PubMed Web of Science ®Google Scholar
• ••First published account of a transcriptionfactor that is directly regulated by Ca2±. DREAM can bind directly to DNA and repress transcription, both of which are abrogated when Ca2+ associates with DREAM's EF-hand domains. This study established a new paradigm in Ca-dependent gene expression.
   Google Scholar
• AN WE BOWLBY MR, BETTY M et al: Modulation of A-type potassium channels by a family of calcium sensors. Nature (2000) 403:553–556.
   PubMedGoogle Scholar
• •KChIPs, a family of potassium channel-interacting proteins, are discovered. KChlPs may be involved in the trafficking of Kv4 potassium channel subunits to the plasma membrane, in addition to directly modulating current kinetics.
   Google Scholar
• CHENG HY, PITCHER GM, LAVIOLETTE SR et al: DREAM is a critical transcriptional repressor for pain modulation. Cell (2002) 108:31–43.
   PubMed Web of Science ®Google Scholar
• ••The physiological function of DREAM isexamined using a genetic approach. DREAM knockout mice exhibit attenuated pain behaviour in acute and chronic pain models. The hypoalgesia is attributed to enhanced 1-opiate receptor activation as a result of increased prodynorphin expression in the spinal cords of dream"-mice. This study highlights the essential contribution of DREAM to pain modulation, owing to its role as a transcriptional repressor for prodynorphin.
   Google Scholar
• SCHELLENBERG GD, BIRD TD, WIJSMAN EM et al.: Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science (1992) 258:668–671.
   PubMed Web of Science ®Google Scholar
• SHERRINGTON R, ROGAEV El, LIANG Y et al.: Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer disease. Nature (1995) 375:754–760.
   PubMed Web of Science ®Google Scholar
• LEVY-LAHAD E, WASCO W, POORKAJ P et al.: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 269:973–977.
   PubMed Web of Science ®Google Scholar
• KOVACS DM, FAUSETT HJ, PAGE KJ etal.: Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat. Med. (1996) 2:224–229.
   Google Scholar
• LI YM, XU M, LAI MT et a/.: Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 405:689–694.
   Google Scholar
• ZHANG Z, NADEAU P, SONG W et al: Presenilins are required for gamma-secretase cleavage of 3-APP and transmembrane cleavage of Notch-I. Nat. Cell. Biol. (2000) 2:463–465.
   PubMed Web of Science ®Google Scholar
• WOLOZIN B, IWASAKI K, VITO P et al:Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science (1996) 274: 1710-1713.
   Google Scholar
• VITO P, LACANA E, D'ADAMIO L: Interfering with apoptosis: Ca(2)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science (1996) 271:521–525.
   PubMed Web of Science ®Google Scholar
• KIM TW, PETTINGELL WH, JUNG YK, KOVACS DM, TANZI RE: Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science (1997) 277:373–376.
   PubMed Web of Science ®Google Scholar
• GUO Q, SOPHER BL, FURUKAWA K etal.: Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid 13-peptide: involvement of calcium and oxyradicals. j Neurosci. (1997) 17:4212–4222.
   Google Scholar
• KELLER JN, GUO Q, HOLTSBERG FW,BRUCE-KELLER AJ, MATTSON MP: Increased sensitivity to mitochondria' toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. j Neurosci. (1998) 18:4439–4450.
   PubMed Web of Science ®Google Scholar
• VACCARINO AL, KASTIN AJ: Endogenous opiates: 2000. Peptides (2001) 22:2257–2328.
   PubMed Web of Science ®Google Scholar
• DOUGLASS J, MCKINZIE AA, POLLOCK KM: Identification of multiple DNA elements regulating basal and protein kinase A-induced transcriptional expression of the rat prodynorphin gene. Mol. Endocnnol (1994) 8:333–344.
   PubMedGoogle Scholar
• NARANJO JR, MELLSTROM B, ACHAVAL M, SASSONE-CORSI P: Molecular pathways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene. Neuron (1991) 6:607–617.
   PubMedGoogle Scholar
• MCMURRAY CT, DEVI L, CALAVETTA L, DOUGLASS JO: Regulated expression of the prodynorphin gene in the R2C Leydig tumor cell line. Endocrinology (1989) 124:49–59.
   PubMedGoogle Scholar
• CARRION AM, MELLSTROM B, LUCKMAN SM, NARANJO JR: Stimulus-specific hierarchy of enhancer elements within the rat prodynorphin promoter. J. Neurochent. (1998) 70:914–921.
   PubMedGoogle Scholar
• MESSERSMITH DJ, KIM DJ, IADAROLA MJ: Transcription factor regulation of prodynorphin gene expression following rat hindpaw inflammation. Brain Res. Ma Brain Res. (1998) 53:260–269.
   PubMedGoogle Scholar
• COLLINS-HICOK J, LIN L, SPIRO C et al.: Induction of the rat prodynorphin gene through Gs-coupled receptors may involve phosphorylation-dependent derepression and activation. Ma Cell. Biol. (1994) 14:2837–2848.
   Google Scholar
• CARRION AM, MELLSTROM B, NARANJO JR: Protein kinase A-dependent derepression of the human prodynorphin gene via differential binding to an intragenic silencer element. Ma Cell. Biol. (1998) 12:6921–6929.
   Google Scholar
• •The first indication that both basal and inducible expression of the prodynorphin gene are under the regulation of a downstream cis element, whose binding to a nuclear factor(s) results in transcriptional repression.
   Google Scholar
• SHIBATA R, NAKAHIRA K, SHIBASAKI K, WAKAZONO Y, IMOTO K, IKENAKA K: A-type K+ current mediated by the Kv4 channel regulates the generation of action potential in developing cerebellar granule cells. Neurosci. (2000) 20:4145–4155.
   Google Scholar
• JOHNS DC, NUSS HB, MARBAN E: Suppression of neuronal and cardiac transient outward currents by viral gene transfer of dominant-negative Kv4.2 constructs. J. Biol. Chem. (1997) 272:31598–31603.
   PubMedGoogle Scholar
• HOFFMAN DA, MAGEE JC, COLBERT CM, JOHNSTON D: KE channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons. Nature (1997) 387:869–875.
   PubMed Web of Science ®Google Scholar
• RAMAKERS GM, STORM JF: A postsynaptic transient KE current modulated by arachidonic acid regulates synaptic integration and threshold for LTP induction in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. USA (2002) 99:10144–10149.
   PubMed Web of Science ®Google Scholar
• DIXON JE, SHI W, WANG HS et al.: Role of the Kv4.3 KE channel in ventricular muscle. A molecular correlate for the transient outward current. Circ. Res. (1996) 79:659–668.
   Google Scholar
• HOPPE UC, MARBAN E, JOHNS DC: Molecular dissection of cardiac repolarization by in vivo Kv4.3 gene transfer. J. OM. Invest. (2000) 105:1077–1084.
   PubMedGoogle Scholar
• YAN GX, ANTZELEVITCH C: Cellular basis for the electrocardiographic J wave. Circulation (1996) 93:372–379.
   PubMed Web of Science ®Google Scholar
• NABAUER M, BEUCKELMANN DJ, UBERFUHR P, STEINBECK G: Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation (1996) 93:168–177.
   PubMed Web of Science ®Google Scholar
• ROSATI B, PAN Z, LYPEN S et al.: Regulation of KChIP2 potassium channel 13 subunit gene expression underlies the gradient of transient outward current in canine and human ventricle. J. Physiol. (2001) 533:119–125.
   PubMed Web of Science ®Google Scholar
• SPREAFICO E BARSKI JJ, FARINA C, MEYER M: Mouse DREAM/calsenilin/ KChIP3: gene structure, coding potential, and expression. Md. Cell. Neurosci. (2001) 17:1–16.
   PubMedGoogle Scholar
• OHTA T, KOBAYASHI M, HIROSE S: Cloning of a cDNA for DNA supercoiling factor reveals a distinctive Ca(21-binding protein. J. Biol. Chem. (1995) 270:15571–15575.
   PubMedGoogle Scholar
• KOBAYASHI M, AITA N, HAYASHI S, OKADA K, OHTA T, HIROSE S: DNA supercoiling factor localizes to puffs on polytene chromosomes in Drosophila melanogaster Md. Cell. Biol. (1998) 18:6737–6744.
   Google Scholar
• KOBAYASHI M, HIROSE S: Functional dissection of DNA supercoiling factor: EF-hand domains and C-terminal HDEF motif are essential for its activity. Genes Cells. (1999) 4:33–40.
   PubMedGoogle Scholar
• SCHRADER LA, ANDERSON AE, MAYNE A et al.: Modulation of Kv4.2 current by KChIP3 and PKA activation. 31st Annual Meeting of the Soden, for Neuroscience, San Diego, USA, Vol. 27. Abstract.
   Google Scholar
• CHOI EK, MILLER JS, ZAIDI NF et al.:Functional role of post-translational modification of calsenilin in Alzheimer's disease. 31st Annual Meeting of the Society for Neuroscience, San Diego, CA, Volume 27. Abstract.
   Google Scholar
• TAKIMOTO K, YANG EK, CONFORTI L: Palmitoylation of KChIP splicing variants is required for efficient cell surface expression of Kv4.3 channels. J. Biol. Chem. (2002) 277:26904–26911.
   PubMed Web of Science ®Google Scholar
• SANZ C, MELLSTROM B, LINK WA, NARANJO JR, FERNANDEZ-LUNA JL: Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic hrk gene in hematopoietic progenitor cells. EMBO (2001) 20:2286–2292.
   PubMed Web of Science ®Google Scholar
• OSAWA M, TONG KI, LILLIEHOOK C et al.: Calcium-regulated DNA binding and oligomerization of the neuronal calcium-sensing protein, calsenilin/DREAM/ KChIP3. _J. Biol. Chem. (2001) 276:41005–41013.
   PubMed Web of Science ®Google Scholar
• CRAIG TA, BENSON LM, VENYAMINOV SY etal.: The metal-binding properties of DREAM: evidence for calcium-mediated changes in DREAM structure. J. Biol. Chem. (2002) 277:10955–10966.
   Google Scholar
• IKURA M, OSAWA M, AMES JB: The roleof calcium-binding proteins in the control of transcription: structure to function. Bioessays (2002) 24:625–636.
   PubMedGoogle Scholar
• LEDO F, LINK WA, CARRION AM, ECHEVERRIA V, MELLSTROM B, NARANJO JR: The DREAM-DRE interaction: key nucleotides and dominant negative mutants. Biochim. Biophys. Acta. (2000) 1498:162–168.
   PubMedGoogle Scholar
• MESSERSMITH DJ, GU J, DUBNER R, DOUGLASS J, IADAROLA MJ: Basal and inducible transcriptional activity of an upstream AP-1/CRE element (DYNCRE3) in the prodynorphin promoter. Md. Cell. Neurosci. (1994) 5:238–245.
   PubMedGoogle Scholar
• LEDO F, CARRION AM, LINK WA, MELLSTROM B, NARANJO JR: DREAM-aCREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription. Ma. Cell. Biol. (2000) 20:9120–9126.
   Google Scholar
• DE CESARE D, FIMIA GM, SASSONE-CORSI P: Signaling routes to CREM and CREB: plasticity in transcriptional activation. Trends Biochem. Li. (1999) 24:281–285.
   PubMedGoogle Scholar
• DELMAS V, LAOIDE BM, MASQUILIER D, DE GROOT RE FOULKES NS, SASSONE-CORSI P: Alternative usage of initiation codons in mRNA encoding the cAMP-responsive-element modulator generates regulators with opposite functions. Proc. Nati Acad. Sci. USA (1992) 89:4226–4230.
   PubMedGoogle Scholar
• MOLINA CA, FOULKES NS, LALLI E, SASSONE-CORSI P: Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell (1993) 75:875–886.
   PubMedGoogle Scholar
• HEERY DM, KALKHOVEN E, HOARE S, PARKER MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (1997) 387:733–736.
   PubMed Web of Science ®Google Scholar
• DE GROOT RE BALLOU LM, SASSONE-CORSI P: Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell (1994) 79:81–91.
   PubMedGoogle Scholar
• LEDO F, KREMER L, MELLSTROM B, NARANJO JR: Ca2+-dependent block of CREB-CBP transcription by repressor DREAM. EMBO J. (2002) 21:4583–4592.
   PubMed Web of Science ®Google Scholar
• •CREEs transcriptional activity is shown to be under the inhibitory control of DREAM. This study suggests that DREAM may be a nexus between cAMP- and Ca-dependent gene expression.
   Google Scholar
• MAYRB, MONTMINY M: Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev Ma. Cell. Biol. (2001) 2:599–609.
   PubMedGoogle Scholar
• BRUNET A, DATTA SR, GREENBERG ME: Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. (2001) 11:297–305.
   PubMed Web of Science ®Google Scholar
• SANZ C, BENITO A, INOHARA N, EKHTERAE D, NUNEZ G, FERNANDEZ-LUNA JL: Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells. Blood (2000) 95:2742–2747.
   PubMed Web of Science ®Google Scholar
• CODERRE TJ, VACCARINO AL, MELZACK R: Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. Brain Res. (1990) 535:155–158.
   PubMedGoogle Scholar
• ABBADIE C, TAYLOR BK, PETERSON MA, BASBAUM AT: Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain (1997) 69:101–110.
   PubMed Web of Science ®Google Scholar
• SIMONIN F, VALVERDE O, SMADJA C et al.: Disruption of the lc-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective ic-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. (1998) 17:886–897.
   PubMed Web of Science ®Google Scholar
• BURTON MB, GEBHART GF: Effects of lc-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J. Pharmacy]. Exp. Ther. (1998) 285:707–715.
   PubMed Web of Science ®Google Scholar
• SANDNER-KIESLING A, PAN HL et al.:Effect of lc opioid agonists on visceral nociception induced by uterine cervical distension in rats. Pain (2002) 96:13–22.
   PubMed Web of Science ®Google Scholar
• ARNER S, MEYERSON BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain (1988) 33:11–23.
   PubMed Web of Science ®Google Scholar
• KUPERS RC, KONINGS H, ADRIAENSEN H, GYBELS JM: Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain (1991) 47:5–12.
   PubMed Web of Science ®Google Scholar
• JADAD AR, CARROLL D, GLYNN CJ, MOORE RA, MCQUAY HJ: Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet (1992) 339:1367–1371.
   PubMed Web of Science ®Google Scholar
• PORTENOY RK, FOLEY KM, INTURRISI CE: The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain (1990) 43:273–286.
   PubMed Web of Science ®Google Scholar
• BENEDETTI E VIGHETTI S, AMANZIO M et al.: Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain (1998) 74:205–211.
   PubMedGoogle Scholar
• MOSCONI T, KRUGER L: Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations. Pain (1996) 64:37–57.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, OHTORI S, CHIBA T: Effects of pre-emptively administered nociceptin on the development of thermal hyperalgesia induced by two models of experimental mononeuropathy in the rat. Brain Res. (2000) 871:192–200.
   PubMedGoogle Scholar
• SAVAGE SR: Opioid use in the management of chronic pain. Med. Clin. North. Am. (1999) 83:761–786.
   PubMed Web of Science ®Google Scholar
• BENNETT J, WREN KR, HAAS R: Opioid use during the perianesthesia period: nursing implications. J. Perianesth. Nurs. (2001) 16:255–258.
   PubMedGoogle Scholar
• DAY R, LAZURE C, BASAK A et al.: Prodynorphin processing by proprotein convertase 2. Cleavage at single basic residues and enhanced processing in the presence of carboxypeptidase activity. I Biol. Chem. (1998) 273:829–836.
   Google Scholar
• BERMAN Y, MZHAVIA N, POLONSKAIA A et al.: Defective prodynorphin processing in mice lacking prohormone convertase PC2. J. Neurochem. (2000) 75:1763–1770.
   PubMedGoogle Scholar
• SILBERRING J, CASTELLO ME, NYBERG F: Characterization of dynorphin A-converting enzyme in human spinal cord. An endoprotease related to a distinct conversion pathway for the opioid heptadecapeptide? J. Biol. Chem. (1992) 267:21324–21328.
   Google Scholar
• CABOT PJ, CARTER L, SCHAFER M, STEIN C: Methionine-enkephalin and dynorphin A-release from immune cells and control of inflammatory pain. Pain (2001) 93:207–212.
   PubMed Web of Science ®Google Scholar
• DAWSON-BASOA M, GINTZLER AR: Gestational and ovarian sex steroid antinociception: synergy between spinal lc and 8 opioid systems. Brain Res. (1998) 794:61–67.
   PubMed Web of Science ®Google Scholar
• GUPTA DS, KELSON AB, POLGAR WE,TOLL L, SZUCS M, GINTZLER AR: Ovarian sex steroid-dependent plasticity of nociceptin/orphanin FQ and opioid modulation of spinal dynorphin release. Pharmacol. Exp. Ther. (2001) 298:1213–1220.
   PubMedGoogle Scholar
• MEDINA VM, DAWSON-BASOA ME, GINTZLER AR: 1713-estradiol and progesterone positively modulate spinal cord dynorphin: relevance to the analgesia of pregnancy. Neutvendocrinology (1993) 58:310–315.
   PubMedGoogle Scholar
• VARSHNEY C, RIVERA M, GINTZLER AR: Modulation of prohormone convertase 2 in spinal cord during gestation and hormone-simulated pregnancy. Neuroendocrinology (1999) 70:268–279.
   PubMedGoogle Scholar
• XIN L, GELLER EB, ADLER MW: Body temperature and analgesic effects of selective mu microdialyzed into rat brain. Pharmacol. Exp. Ther. (1997) 281:499–507.
   PubMedGoogle Scholar
• PASTERNAK KR, ROSSI GC, ZUCKERMAN A, PASTERNAK GW: Antisense mapping KOR-1: evidence for multiple lc analgesic mechanisms. Brain Res. (1999) 826:289–292.
   PubMedGoogle Scholar
• HAN JS, CHEN XH, SUN SL etal.: Effect of low- and high-frequency TENS on Met-enkephalin-Arg-Phe and dynorphin A immunoreactivity in human lumbar CSF. Pain (1991) 47:295–298.
   Google Scholar
• HAN JS, XIE GX: Dynorphin: important mediator for electroacupuncture analgesia in the spinal cord of the rabbit. Pain (1984) 18:367–376.
   PubMed Web of Science ®Google Scholar
• OMIYA Y, GOTO K, SUZUKI Y, ISHIGE A, KOMATSU Y: Analgesia-producing mechanism of processed Aconiti tuber: role of dynorphin, an endogenous 1c-opioid ligand, in the rodent spinal cord. bit. I Pharmacol. (1999) 79:295–301.
   Google Scholar
• SUZUKI Y, GOTO K, ISHIGE A, KOMATSU Y, KAMEI J: Antinociceptive effect of Gosha-jinki-gan, a Kampo medicine, in streptozotocin-induced diabetic mice. bit. I Pharmacol. (1999) 79:169–175.
   Google Scholar
• HOUSER SJ, EADS M, EMBREY JP, WELCH SP: Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, A(9)-THC and anandamide. Brain Res. (2000) 857:337–342.
   PubMedGoogle Scholar
• PUGH G Jr, SMITH PB, DOMBROWSKI DS, WELCH SP: The role of endogenous opioids in enhancing the antinociception produced by the combination of 89-tetrahydrocannabinol and inflammation in the rat. Brain Res. (1996) 710:131–142.
   PubMedGoogle Scholar
• PUGH G JR, ABOOD ME, WELCH SP: Antisense oligodeoxynucleotides to the lc-1 receptor block the antinociceptive effects of 49-THC in the spinal cord. Brain Res. (1995) 689:157–158.
   PubMedGoogle Scholar
• DRAISCI G, KAJANDER KC, DUBNER R, BENNETT GJ, IADAROLA MJ: Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. Brain Res. (1991) 560:186–192.
   PubMed Web of Science ®Google Scholar
• LAUGHLIN TM, LARSON AA, WILCOX GL: Mechanisms of induction of persistent nociception by dynorphin. J Pharmacol. Exp. Ther. (2001) 299:6–11.
   PubMedGoogle Scholar
• TANG Q, GANDHOKE R, BURRITT A, HRUBY VJ, PORRECA F, LAI J: High-affinity interaction of (des-tyrosyl)dynorphin A(2-17) with NMDA receptors. J. Pharmacol. Exp. Ther. (1999) 291:760–765.
   PubMedGoogle Scholar
• LAUGHLIN TM, VANDERAH TW, LASHBROOK J et al.: Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain (1997) 72:253–260.
   PubMedGoogle Scholar
• SHARIFI N, DIEHL N, YASWEN L, BRENNAN MB, HOCHGESCHWENDER U: Generation of dynorphin knockout mice. Brain Res. Md. Brain Res. (2001) 86:70–75.
   PubMedGoogle Scholar
• WANG Z, GARDELL LR, OSSIPOV MH et al.: Pronociceptive actions of dynorphin maintain chronic neuropathic pain. JNeurosci. (2001) 21:1779–1786.
   PubMedGoogle Scholar
• GAUMANN DM, GRABOW TS, YAKSH TL, CASEY SJ, RODRIGUEZ M: Intrathecal somatostatin, somatostatin analogs, substance P analog and dynorphin A cause comparable neurotoxicity in rats. Neuroscience (1990) 39:761–774.
   PubMed Web of Science ®Google Scholar
• TAYLOR JS, MORCUENDE S, NARANJO JR: Molecular pain of pain: "knockdown" of the prodynorphin gene reveals an involvement in antinociception. In: Molecular Neurobiology of Pain, Progress in Pain Research and Management (Vol. 9). Borsook D (Ed.), IASP Press, Seattle (1997):201–218.
   Google Scholar
• RILEY RC, ZHAO ZQ, DUGGAN AW: Spinal release of immunoreactive dynorphin A(1–8) with the development of peripheral
   Google Scholar
• HU WH, ZHANG CH, YANG HF et al.: Mechanism of the dynorphin-induced dualistic effect on free intracellular Ca2+
   Google Scholar
• MOROHASHI Y, HATANO N, OHYA S et al.: Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with
   Google Scholar
• GUO W, MALIN SA, JOHNS DC, JEROMIN A, NERBONNE JM: Modulation of Kv4-encoded KM currents in
   Google Scholar
• LILLIEHOOK C, CHAN S, CHOI EK et al.: Calsenilin enhances apoptosis by altering endoplasmic reticulum calcium
   Google Scholar
• JO DG, KIM MJ, CHOI YH et al.: Pro-apoptotic function of calsenilin/ DREAM/KChIP3. FASEB J. (2001) 15:589–591.
   PubMedGoogle Scholar
• LEISSRING MA, YAMASAKI TR, WASCO W, BUXBAUM JD, PARKER I, LAFERLA FM: Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proc. Natl. Acad. Sci. USA (2000) 97:8590–8593.
   PubMed Web of Science ®Google Scholar
• MATTSON MP, LAFERLA FM, CHAN SL, LEISSRING MA, SHEPELPN, GEIGER JD: Calcium signaling in the ER: its role in neuronal plasticity and
   Google Scholar
• ESLER WP KIMBERLY WT, OSTASZEWSKI BL et al.: Activity-dependent isolation of the presenilin- gamma-secretase complex reveals nicastrin and a gamma substrate. Proc. Natl. Acad. Sci. USA (2002) 99:2720–2725.
   PubMedGoogle Scholar
• HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative memory deficits, AP elevation, and amyloid plaques in transgenic mice. Science (1996) 274:99–102.
   PubMed Web of Science ®Google Scholar
• CHUI DH, TANAHASHI H, OZAWA K et al.: Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. (1999) 5:560–564.
   PubMed Web of Science ®Google Scholar
• KUO HC, CHENG CF, CLARK RB et al.: HURD YL: Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Ma. Psychiatry (2002) 7:75–81.
   Google Scholar
• DESCHENES I, DISILVESTRE D, JUANG GJ, WU RC, AN WF, TOMASELLI GF: Regulation of Kv4.3 current by KChIP2 splice variants: a component of native cardiac I(to)? Circulation (2002) 106:423–429.
   Google Scholar
• ZIMPRICH A, KRAUS J, WOLTJE M, MAYER P, RAUCH E, HOLLT V: An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J. Neurochem. (2000) 74:472–477.
   PubMedGoogle Scholar
• CHEN AC, LAFORGE KS et al.: Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am. J. Med. Genet. (2002) 114:429–435.
   PubMed Web of Science ®Google Scholar
• STOGMANN E, ZIMPRICH A, BAUMGARTNER C, AULL-WATSCHINGER S, HOLLT V, ZIMPRICH F: A functional polymorphism in the prodynorphin gene promotor is associated with temporal lobe epilepsy. Ann. Neurol. (2002) 51:260–263.
   PubMed Web of Science ®Google Scholar
• CARLEZON WA JR, THOME J, OLSON VG et al.: Regulation of cocaine reward by CREB. Science (1998) 282:2272–2275.
   PubMedGoogle Scholar
• HURD YL: Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Mol. Psychiatry (2002) 7:75–81.
   PubMedGoogle Scholar
• LIN CR, YANG LC, LEE TH et al.: Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther. (2002) 9:1247–1253.
   PubMedGoogle Scholar
• WILSON SP, YEOMANS DC, BENDER MA, LU Y, GOINS WF, GLORIOSO JC: Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc. Nati Acad. Sci. USA (1999) 96:3211–3216.
   PubMed Web of Science ®Google Scholar
• BRIDGES D, THOMPSON SW, RICE AS: Mechanisms of neuropathic pain. Br. J. Arraesth. (2001) 87:12–26.
   PubMedGoogle Scholar
• CHENG HYM, PENNINGER JM: Transcriptional mechanisms underlying neuropathic pain: DREAM, transcription factors and future pain management? Expert Rev Neurotherapeutics (2002) 2:89-101. A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia. Cell (2001) 107:801-813. DESCHENES I, DISILVESTRE D, JUANG GJ, WU RC, AN WF, TOMASELLI GF: Regulation of Kv4.3 current by KChIP2 splice variants: a component of native cardiac I(to)? Circulation (2002) 106:423-429. ZIMPRICH A, KRAUS J, WOLTJE M, MAYER P, RAUCH E, HOLLT V: An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J. Neurochem. (2000) 74:472-477. CHEN AC, LAFORGE KS et al.: Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am. J. Med. Genet. (2002) 114:429-435. STOGMANN E, ZIMPRICH A, BAUMGARTNER C, AULL-WATSCHINGER S, HOLLT V, ZIMPRICH F: A functional polymorphism in the prodynorphin gene promotor is associated with temporal lobe epilepsy. Ann. Neurol. (2002) 51:260-263. morphine in the spinal cord. J Pharmacol. Exp. Ther. (1996) 279:608–616.
   Google Scholar
• •Comprehensive review on gene expression changes and the involvement of specific transcription factors in neuropathic pain states.
   Google Scholar
• MANSOUR A, HOVERSTEN MT, TAYLOR LP, WATSON SJ, ARIL H: The cloned d, 8 and x receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. (1995) 700:89–98.
   PubMed Web of Science ®Google Scholar